The relation of the gonadotrophin response to chlormadinone according to body weight in patients with amenorrhea due to polycystic ovarian syndrome

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 66, Issue 2, 1996, Pages 161-164

  Carranza Lira, Sebastián ^a,b   García Hernández, Edgardo ^a   Baiza, María R ^a   Morán, Carlos ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b Col Toriello Guerra ^*  (Mexico)

Author keywords

Chlormadinone; Gonadotrophin; Obesity; Progestogen

Indexed keywords

CHLORMADINONE; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE;

ADULT; AMENORRHEA; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; UTERUS BLEEDING;

EID: 0343832020     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-2115(96)02398-6     Document Type: Article

References (16)

1. Mishell DR, Odell WD. Effect of varying dosages of ethynodiol diacetate upon serum luteinizing hormone. Am J Obstet Gynecol 1971; 109: 140-149.
2. Franchimont P, Cession G, Ayalon D et al. Suppressive action of norethisterone enanthate and acetate on gonadotropin (FSH and LH) levels. Obstet Gynecol 1970; 36: 93-100.
3. Goldenberg RL, Grodin JM, Vaitukaitis JL et al. Withdrawal bleeding and luteinizing hormone secretion following progesterone in women with amenorrhea. Am J Obstet Gynecol 1973; 115: 193-195.
4. Petsos P, Ratcliffe WA, Anderson DC. Effects of medroxyprogesterone acetate in women with polycystic ovary syndrome. Clin Endocrinol 1986; 25: 651-660.
5. Heineman MJ, Thomas CMG, Doesburg WH et al. Hormonal characteristics of women with clinical features of the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 1984; 17: 263-271.
6. Anttila L, Koskunen P, Kaihola HL et al. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries. Fertil Steril 1992; 58: 697-702.
7. Wortsman J, Khan MS, Rosner W. Supression of testosterone-estradiol binding globulin by medroxyprogesterone acetate in polycystic ovary syndrome. Obstet Gynecol 1986; 67: 705-709.
8. Anttila L, Ding YQ, Ruutiainen K et al. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian syndrome. Fertil Steril 1991; 55: 1057-1061.
9. Adams J, Poison DW, Abdulwahid N et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone. Lancet 1985; 21: 1375-1379.
10. Bray GA. Overweight is risking fate. Ann NY Acad Sci 1987; 499: 14-28.
11. Morán C, Hernández E, Ruiz JE et al. La distribución del tejido adiposo tiene relación con los niveles de insulina en la mujer obesa. Ginecol Obstet Mex 1992; 60: 75-80.
12. Moncada-Lorenzo E. Familial study of hirsutism. J Clin Endocr 1970; 31: 556-564.
13. Dunaif A, Seigel KR, Futterwit W et al. Profound peripheral insulin resistance independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174.
14. Lanzone A, Fulghesu AM, Guido M, et al. Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion. Fertil Steril 1992; 58: 296-303.
15. Ehrmann DA, Rosenfield RL, Barnes RB et al. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992; 327: 157-162.
16. Grenman S, Rönnemaa T, Irjala K et al. Sex steroid, gonadotropin, cortisol, and prolactin levels in healthy, massively obese women: correlation with abdominal fat cell size and effect of weight reduction. J Clin Endocrinol Metab 1986; 63: 1257-1261.